Retatrutide is one molecule activating three post-meal receptor systems — GIP, GLP-1, and glucagon. Tirzepatide activates two; retatrutide adds glucagon, and that single addition is why liver fat, triglycerides, kidney markers, and heart rate all move more than on the approved class. Its effects on appetite, liver fat, heart rate, and tolerability also change with dose, and the headline trial results come from one population — sedentary, non-diabetic adults averaging ~110 kg (BMI 37) — so they don't transfer directly to leaner users.
What Retatrutide Is
Native GIP, GLP-1, and glucagon fire for minutes after a meal or during a fast, then clear. Retatrutide has a six-day half-life, holding all three receptors engaged around the clock — brief natural pulses become steady, continuous pressure. The GIP receptor governs how fat cells handle energy and dampens nausea via a brainstem brake circuit. The GLP-1 receptor drives appetite suppression and slows the stomach (and sets tolerability — nausea is the limiting signal). The glucagon receptor tells the liver to burn stored fat, defends resting metabolism against the post-weight-loss drop, and carries most of the heart-rate rise. ("GLP-3" is not a real drug class — the name just counts receptors; what matters is the glucagon arm.)
How the Three Receptors Engage
The three receptors don't engage at the same rate, so higher doses shift which receptor does the marginal work rather than doing more of one thing. The GIP receptor saturates early (retatrutide binds it far more tightly than tirzepatide). GLP-1 engagement climbs across the whole range (appetite suppression and nausea keep rising). Glucagon scales last, reaching continuous above-native engagement only at upper doses — where liver-fat reduction and the heart-rate cost concentrate. At low doses it acts mostly as a GIP-receptor drug with a light appetite signal; at the top of the range the GIP arm is saturated and the extra exposure adds appetite pressure plus the glucagon liver-and-heart signal.
How Much Weight Loss to Expect
Headline figures: 24.2% mean weight loss over 48 weeks (Phase 2) and 28.7% over 68 weeks (Phase 3 TRIUMPH-4, obesity with osteoarthritis), both at the top dose. The response is a curve, not a line — gains flatten toward the top of the dose range. Trajectory is gradual (week-24 loss is ~three-quarters of the eventual result; liver-fat reduction still moving at week 48). Women lose meaningfully more than men at the same dose (~4 kg advantage, the largest of any compound studied), and effect declines ~3% per year above age 50. A lean recomposition user should expect smaller absolute loss (no chronic trial has measured that population).
Liver Fat
The glucagon arm makes retatrutide a liver drug, not just a weight drug — glucagon signals the liver to oxidize its own stored fat, which semaglutide and tirzepatide can't do. In the MASLD substudy (≥10% liver fat), liver fat fell 51% at the lowest dose and 86% at the top dose over 48 weeks, with steatosis resolving in 93% at top dose. The effect is substrate-gated: a fatty liver has fat to mobilize (large reduction), while a lean person shows the same fat-burning signal (rising ketones) but little liver fat to deplete. The glucagon arm also lowers triglycerides (~60%) and LDL (~25%) at top dose by releasing the brake on a fat-clearing enzyme (ANGPTL3/8 suppression).
Body Composition
Not all weight lost is fat. Across the class, about a quarter of weight lost is fat-free mass (roughly half of that skeletal muscle) — a bigger concern for lean users. Resistance training and adequate protein help preserve it.
Side Effects
Two receptor sources. The GLP-1 arm drives familiar GI effects (nausea, vomiting, diarrhea, slowed digestion) that scale with dose, peak during dose escalation, and partially settle. The glucagon arm adds effects the GLP-1 class doesn't: a burning/tingling skin sensitivity (dysesthesia) at upper doses, and suppression of active thyroid hormone presenting as unexplained fatigue or cold intolerance — because it lowers free T3 while leaving TSH normal, free T3 is the marker to check. Honest limitation: trial adverse-event tables are pre-specified inventories, so commonly searched symptoms like hair loss sit outside the captured set — the data is genuinely silent, not reassuring.
Heart Rate
The heart-rate rise is real and mostly the glucagon arm. The GLP-1 class alone raises resting HR only 2–4 bpm even at max; retatrutide's larger signal sits on top of that and tracks glucagon engagement. In the obese cohort it peaked ~6–9 bpm at the top dose near week 24, then eased toward ~5 bpm by week 48 as weight loss rebalanced the system. The phenotype split matters most here: a lean, fit person's more responsive cardiovascular system can land the same glucagon engagement several times harder, with no compensating weight-loss decline. Pre-existing atrial fibrillation or known structural heart disease is a clear reason not to use retatrutide.
What Happens After Stopping
Stopping doesn't cause a physical withdrawal syndrome but does set up weight regain, expected to be stronger than with semaglutide or tirzepatide. Four forces converge: appetite returns as the drug clears over ~30 days; lost lean mass lowers daily energy use; hunger-hormone signals stay elevated up to a year after major weight loss; and, unique to retatrutide, the glucagon-driven defense of resting metabolism fades within weeks. No published tapering protocol exists.
Retatrutide vs Tirzepatide
The mechanistic difference is one receptor: retatrutide adds the glucagon arm tirzepatide doesn't engage and binds the GIP receptor far more tightly. The glucagon arm gives retatrutide its liver-fat reduction, resting-metabolism defense, and larger heart-rate cost. On weight loss the head-to-head hasn't read out; cross-trial at top doses, tirzepatide ~21% over 72 weeks vs retatrutide 24% over 48 weeks (Phase 2) and 29% in TRIUMPH-4 — numbers favor retatrutide but cohort/length differences make a precise gap unreliable until the direct comparison reports.